The Luxturna Debate: Why Ethics Needs a Seat at the Drug Pricing Table

The Luxturna Debate: Why Ethics Needs a Seat at the Drug Pricing Table | Bill of Health

This article presents one genetics therapy for a disease with a neurological basis; the treatment apparently has good effects but the details in the report do not explain how the treatment works. There is an extensive amount of bureaucratese raising some of the myriad of issues related to gene therapy. Nicer to read than most articles but this one is not a cure for amyotrophic lateral sclerosis.